Log in

NASDAQ:MNLOMenlo Therapeutics Stock Price, Forecast & News

$2.21
+0.08 (+3.76 %)
(As of 06/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.06
Now: $2.21
$2.23
50-Day Range
$1.29
MA: $1.83
$2.51
52-Week Range
$1.00
Now: $2.21
$7.48
Volume5.19 million shs
Average Volume2.39 million shs
Market Capitalization$301.13 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2
Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is headquartered in Redwood City, California.
Read More
Menlo Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MNLO
CUSIPN/A
Phone650-486-1416

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.64 million
Book Value$2.81 per share

Profitability

Net Income$-73,700,000.00

Miscellaneous

Employees43
Market Cap$301.13 million
Next Earnings Date8/6/2020 (Estimated)
OptionableNot Optionable

Receive MNLO News and Ratings via Email

Sign-up to receive the latest news and ratings for MNLO and its competitors with MarketBeat's FREE daily newsletter.

Menlo Therapeutics (NASDAQ:MNLO) Frequently Asked Questions

How has Menlo Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Menlo Therapeutics' stock was trading at $3.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MNLO stock has decreased by 33.0% and is now trading at $2.21. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Menlo Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Menlo Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Menlo Therapeutics.

When is Menlo Therapeutics' next earnings date?

Menlo Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Menlo Therapeutics.

How were Menlo Therapeutics' earnings last quarter?

Menlo Therapeutics Inc (NASDAQ:MNLO) issued its quarterly earnings results on Monday, May, 11th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.54) by $0.41. The business earned $1.75 million during the quarter, compared to analyst estimates of $2.21 million. View Menlo Therapeutics' earnings history.

What price target have analysts set for MNLO?

4 Wall Street analysts have issued 12-month price objectives for Menlo Therapeutics' stock. Their forecasts range from $3.00 to $8.00. On average, they anticipate Menlo Therapeutics' stock price to reach $5.13 in the next twelve months. This suggests a possible upside of 131.9% from the stock's current price. View analysts' price targets for Menlo Therapeutics.

Has Menlo Therapeutics been receiving favorable news coverage?

News stories about MNLO stock have trended negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Menlo Therapeutics earned a news sentiment score of -2.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutMenlo Therapeutics.

Who are some of Menlo Therapeutics' key competitors?

What other stocks do shareholders of Menlo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Menlo Therapeutics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Opko Health (OPK), Shopify (SHOP), AbbVie (ABBV), Advanced Micro Devices (AMD), DexCom (DXCM), Aquestive Therapeutics (AQST) and salesforce.com (CRM).

Who are Menlo Therapeutics' key executives?

Menlo Therapeutics' management team includes the following people:
  • Mr. Steven L. Basta, Pres, CEO & Director (Age 53)
  • Ms. Kristine M. Ball CPA, Sr. VP of Corp. Strategy & CFO (Age 47)
  • Dr. Mary C. Spellman, Chief Medical Officer (Age 57)
  • Dr. Paul S. Kwon M.D., Chief Scientific Officer (Age 48)
  • Mr. Stuart D. Sedlack M.B.A., VP of Bus. Devel. (Age 54)

When did Menlo Therapeutics IPO?

(MNLO) raised $86 million in an initial public offering on Thursday, January 25th 2018. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Piper Jaffray and Guggenheim Securities served as the underwriters for the IPO and JMP Securities was co-manager.

What is Menlo Therapeutics' stock symbol?

Menlo Therapeutics trades on the NASDAQ under the ticker symbol "MNLO."

Who are Menlo Therapeutics' major shareholders?

Menlo Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (27.16%), Vivo Capital LLC (15.73%), BlackRock Inc. (12.13%), Orbimed Advisors LLC (7.17%), Morgan Stanley (3.92%) and Morgan Stanley (0.70%). View institutional ownership trends for Menlo Therapeutics.

Which institutional investors are selling Menlo Therapeutics stock?

MNLO stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Russell Investments Group Ltd., and Two Sigma Advisers LP. View insider buying and selling activity for Menlo Therapeutics.

Which institutional investors are buying Menlo Therapeutics stock?

MNLO stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Vivo Capital LLC, BlackRock Inc., Orbimed Advisors LLC, Morgan Stanley, Morgan Stanley, Healthcare Value Capital LLC, and AXA. View insider buying and selling activity for Menlo Therapeutics.

How do I buy shares of Menlo Therapeutics?

Shares of MNLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Menlo Therapeutics' stock price today?

One share of MNLO stock can currently be purchased for approximately $2.21.

How big of a company is Menlo Therapeutics?

Menlo Therapeutics has a market capitalization of $301.13 million and generates $10.64 million in revenue each year. The company earns $-73,700,000.00 in net income (profit) each year or ($3.09) on an earnings per share basis. Menlo Therapeutics employs 43 workers across the globe.

What is Menlo Therapeutics' official website?

The official website for Menlo Therapeutics is www.menlotherapeutics.com.

How can I contact Menlo Therapeutics?

Menlo Therapeutics' mailing address is 200 CARDINAL WAY 2ND FLOOR, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-486-1416 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.